- Laboratoire pharmaceutique : Modèle de Markov coût-utilité interactif sous Excel®, pathologie : Sténose aortique sévère (SAS).
- Laboratoire pharmaceutique : Méta-analyse bayésienne multi-traitements, pathologie : Sténose aortique sévère (SAS).
Salah Ghabri PhD1, Aymeric Binard MD2, Yves-Marie Pers MD3, Franck Maunoury PhD4, J. Jaime Caro MD,CM, FRCPC, FACP567. Economic Evaluation of Sequences of Biological Treatments for Patients With Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response or Intolerance to Methotrexate in France. Value in Health DOI: https://doi.org/10.1016/j.jval.2019.12.003. Available online 13 February 2020.
1 Department of Economic and Public Health Evaluation, French National Authority for Health (HAS), Saint-Denis La Plaine, France 2 Department of Rheumatology, CHU de la Cavale-Blanche, Brest, France 3 Clinical Immunology and Osteoarticular Diseases Therapeutic Unit, Lapeyronie University Hospital, Montpellier, France 4 STATESIA, Le Mans, France 5 McGill University, Montreal, QC, Canada 6 London School of Economics, London, England, UK 7 Evidera, Boston, MA, USA
PRS55 - COST-EFFECTIVENESS OF MEPOLIZUMAB IN SEVERE EOSINOPHILIC ASTHMA PATIENTS IN FRANCE.
F. Maunoury1, C. Pribil2, M. Aubier3, G. Nachbaur2, S. Doyle4
1 STATESIA, Le Mans, France; 2 GlaxoSmithKline, RueilMalmaison, France; 3 Bichat University Hospital, Paris, France; 4 GlaxoSmithKline, London, UK
